Pharma breakthrough! BioIntelect to revolutionise trials using Opyl’s cutting-edge tech

Pallavi Madhiraju- September 25, 2024 0

In a landmark collaboration, Opyl Limited announced a new six-month agreement with BioIntelect, a renowned Clinical Research Organisation (CRO) and strategic consulting firm in the ... Read More

Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Pallavi Madhiraju- September 20, 2024 0

Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More

Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome

Pallavi Madhiraju- September 19, 2024 0

Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted both Rare Pediatric Disease designation and Orphan ... Read More

Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial

Pallavi Madhiraju- September 18, 2024 0

Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. ... Read More

Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids

Pallavi Madhiraju- September 11, 2024 0

Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More

Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails

Pallavi Madhiraju- August 10, 2024 0

AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its workforce by approximately 50%. This decision follows ... Read More

Is the cure for PTSD waiting in the wings? FDA says not yet!

Pallavi Madhiraju- August 10, 2024 0

In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has decided not to approve the use of MDMA, commonly known as ecstasy, ... Read More

HCLTech launches advanced clinical trials solution with Denodo and AWS

Pallavi Madhiraju- August 6, 2024 0

HCLTech, a prominent global technology company, has unveiled a cutting-edge clinical trials and diagnosis solution developed in collaboration with Denodo, a leader in data management, ... Read More

FDA committee endorses Zevra Therapeutics’ arimoclomol as a treatment for Niemann-Pick Disease Type C

Pallavi Madhiraju- August 3, 2024 0

In a notable advancement for rare disease treatment, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has received a significant endorsement from the U.S. Food and Drug Administration ... Read More

$35 million boost for Rona Therapeutics: A new era in RNA medicine begins!

Pallavi Madhiraju- July 20, 2024 0

Rona Therapeutics, a clinical-stage company leading the way in nucleic acid drug research and development, has successfully completed a Series A+ financing round, raising $35 ... Read More